Archive

Highlights from ASH 2019

The American Society of Hematology (ASH) Annual Meeting in 2019, held in Orlando, Florida, as usual gave interesting updates in the management of lymphoma.

Role for ESMO: Access to IO for all?

Late breaking abstracts – Checkmate 227 study

The final analyses of Checkmate 227, part 1 should help to position nivolumab + ipilimumab combination treatment .. Written by Christine Clark

SCLC: is it time for novel therapies?

The search for effective therapeutic targets in small cell lung cancer (SCLC) continues and a number of options have been identified.  In the meantime the results of CASPIAN… read more.

Oligorecurrent and oligoprogressive NSCLC

Oligorecurrent and oligoprogressive NSCLC represent a treatment challenge. A case example of synchronous oligometastatic disease provided the framework for expert discussion……..    Written by Christine Clark.

Immunotherapy in thoracic malignancies: what has been achieved in 2019?

Advances in the use of immunotherapy in thoracic malignancies continued in 2019 with the publication of the results of a number of landmark trials. This has prompted some… read more.

Expert insights in advanced ALK-positive NSCLC

Three expert clinicians, Dr Marina Garassino, Dr Sanjay Popat and Professor Tony Mok presented and discussed cases that illustrated important aspects of the management of ALK-positive NSCLC …… … read more.

Late breaking abstracts – FLAURA study

The final analyses of two key trials – Checkmate 227, part 1 and FLAURA should help to position nivolumab + ipilimumab combination treatment and to reinforce osimertinib as… read more.

Highlights from ESMO 2019

For the second time this year, LungCancer.Med headed to Barcelona for the Annual European Society for Medical Oncology (ESMO) meeting.  Written by Christine Clark

Highlights from IMW 2019

Many of the 4,000 delegates at IMW in Boston this year, such as Professor Mohamad Mohty (Paris, France) highlighted the spirit of collaboration, with locals Professor Paul Richardson and Professor Noopur Raje discussing their highlights… read more.

IMW 2019: Relapsed/refractory myeloma: ongoing challenges and emerging hope

Article written by Tom Collins. Interview by Esther Drain.

Pomalidomide with bortezomib and dexamethasone is one of the best options for multiple myeloma patients who have relapsed while on lenalidomide, but other data are in the offing that could provide even more options, said Professor Philippe Moreau, head of the haematology department at University Hospital in Nantes, France.

IMW 2019: As treatment options explode, questions remain myriad in myeloma

Article written by Tom Collins. Interview by Esther Drain. Meletios Dimopoulos, MD, professor and chairman of clinical therapeutics at the University of Athens and a long-time expert in… read more.